The progress of the global parenteral nutrition market is based on the high prevalence of chronic conditions across the globe. The rise in cancer, AIDS, diabetes, Crohn’s disease, gastro-intestinal disorders, and short bowel syndrome cases has also led a growth in the consumption of parenteral nutrition in the recent years. The World Health Organization (WHO) affirmed this fact with statistics indicating that there will be a 70% rise in the number of new cancer cases between 2025 and 2035. The Crohn’s & Colitis Foundation of America also provided grim figures indicating that there will be 70,000 new cases of Crohn’s disease each year. Thus, the rising health complications will propel the demand for parenteral nutrition across health facilities.
These supportive factors are expected to create an opportunity for this market, which will be worth US$6.9 bn by 2023 as compared to US$4.1 bn in 2014. Between the years 2015 and 2023, this market is expected to expand at a CAGR of 5.7%.
North America was the leading geographical segment in the global parenteral nutrition market as of 2014, accounting for nearly 40.1% share. The high rate of approvals from the U.S. FDA and supportive insurance policies that cover expenditure on parenteral nutrition are expected to keep this region in the leading position during the forecast period. The North America parenteral nutrition market that comprises the U.S. and Canada will also be driven by rising number diabetes and cancer cases. Furthermore, companies are also trying to expand their operations in Canada to gain a stronger foothold by meeting the unmet needs of the patients.
Meanwhile, the parenteral nutrition market in Asia Pacific is expected to surge at the highest pace of 7.3% CAGR between 2015 and 2023. The emerging economies and developing pharmaceutical markets of countries such as China, India, Indonesia, Singapore, Taiwan, and Thailand amongst others are expected to encourage the growth of this market within Asia Pacific. The rising cases of preterm birth, which leads to malnutrition is the prime reason for rising consumption of parenteral nutrition in Asia Pacific.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3611
Out of all the products available in the global parenteral nutrition market, the single dose amino acid solutions nutrient segment captured a significant share of 34.14% in 2014. Research indicates that this segment will be the leading nutrient segment as several leading players are introducing unique amino acid-based PN products. The abundant availability of these products is expected to be the main reason for their soaring success in the forecast period. Reports also suggest that the parenteral lipid emulsion nutrient segment will grow at the highest CAGR of 6.2% amongst all other nutrient segments between 2015 and 2023.
The leading players shaping the vendor landscape of the global parenteral nutrition market are Sichuan Kelun Pharmaceutical Co., Ltd., Allergan plc (Actavis plc), Fresenius SE & Co. KGaA, Grifols S.A., Baxter International, Inc., Claris Lifesciences Limited, and B. Braun Melsungen AG, Pfizer, Inc. (Hospira, Inc.) amongst others. Companies are trying to seek approvals for their new parenteral nutrition formulations from concerned authorities such as the U.S. FDA to launch new products in the market. This effort is focused at both grabbing new market shares and providing for the deficit of parental nutrition in developing regions.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453